New research discovers being underweight later in life is associated with greater deposits of the Alzheimer’s-associated protein beta-amyloid in the brains of cognitively normal older individuals.
Although a cause and effect relationship cannot be determined, the association was particularly strong among individuals carrying the APOE4 gene variant, which is known to increase the risk of Alzheimer’s.
Researchers at Brigham and Women’s Hospital (BWH) and Massachusetts General Hospital (MGH) have published their findings in the Journal of Alzheimer’s Disease.
“Elevated cortical amyloid is believed to be the first stage of the preclinical form of Alzheimer’s disease, so our findings suggest that individuals who are underweight late in life may be at greater risk for this disease,” says Gad Marshall, M.D., senior author of the report.
“Finding this association with a strong marker of Alzheimer’s disease risk reinforces the idea that being underweight as you get older may not be a good thing when it comes to your brain health.”
While the concept of a preclinical version of Alzheimer’s disease is theoretical and not yet being used to guide clinical diagnosis or treatment, the current hypothesis involves three stages.
- Individuals at stage 1 are cognitively normal but have elevated amyloid deposits;
- Stage 2 adds evidence of neurodegeneration, such as elevated tau deposits or characteristic loss of certain brain tissues, with no cognitive symptoms;
- Stage 3 adds cognitive changes that, while still in a normal range, indicate a decline for that individual.
The current study is part of the MGH-based Harvard Aging Brain Study (HABS), designed to identify markers that predict who is likely to develop Alzheimer’s disease and how soon symptoms are likely to develop.
This investigation explored the relationship between body mass index (BMI) and beta amyloid levels in the brains of the first 280 participants to enroll in HABS, who were ages 62 to 90, cognitively normal and in good general health.
Participants’ initial enrollment data included medical histories; physical exams; testing for the presence of APOE4, the major genetic risk factor for late-onset Alzheimer’s; and PET imaging with Pittsburgh compound B (PiB), which can visualize amyloid plaques in the brain.
After adjusting for factors including age, sex, education, and APOE4 status, researchers found that having a lower BMI was associated with greater retention of PiB, indicating more extensive amyloid deposits in the brain.
The relationship was most pronounced in normal-weight participants, who were the group with the lowest BMI in the study. Analysis focused on APOE status revealed that the association between lower BMI and greater PiB retention was particularly significant for individuals with the APOE4 gene variant, which is associated with increased Alzheimer’s disease risk.
Researchers hope that future studies will explain the mechanism behind the association between lower BMI and increased amyloid levels.
“A likely explanation for the association is that low BMI is an indicator for frailty — a syndrome involving reduced weight, slower movement and loss of strength that is known to be associated with Alzheimer’s risk,” says Marshall.
“One way to get closer to determining any cause and effect relationship will be following these individuals over time to see whether their baseline BMI does predict the development of symptoms, which we are doing in HABS, and eventually investigating whether maintaining or even increasing BMI in late life has an effect on outcomes.
Right now, we’re also studying whether BMI is associated with any other clinical and imaging markers of Alzheimer’s disease.”
Source: Massachusetts General Hospital